Cost Study of Hydroprogesterone and Glybenclamide

1346. SHRIMATI KAILASHPATI:
SHRIMATI PRATIBHA SINGH:

Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 1268 given in the Rajya Sabha on 21st May, 1990 and state:

(a) whether it is a fact that Standing Committee has taken a decision on Hydroprogesterone and Glybenclamide;

(b) if so, what are the details thereof;

(c) when was the recommendation of BICP on cost study of Sulphamoxole received;

(d) whether it is a fact that cost study has not been made on factual data; and

(e) if so, what are the details thereof?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) and (b) Recommendation of the Standing Committee with regard to Glybenclamide is under the consideration of the Government. Hydroprogesterone is still under examination by the Standing Committee.

(c) to (e) The recommendations of the Bureau of Industrial Costs and Prices on the fair price of Sulphamoxole were received in June, 1990 and after examination of the report some further details were called from the BICP. These have been received recently. While taking a view on the findings contained in the BICP report all the aspects referred to would be gone into.

Revision of Prices of Analgin based Formulations

1347. SHRIMATI KAILASHPATI : Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) what are the basis followed in revising the price of Analgin based formulations;

(b) what was the earlier price of each and what is their revised price;

(c) whether it is a fact that the criteria has been changed;

(d) if so, what are the reasons therefor;

(e) whether it is also a fact that reduction in price is not even *pro rata* to the reduction in the bulk drug price; and

(f) what steps have been taken to rectify the situation and to fix the responsibility?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) to (e) Consequent upon the decrease in the price of bulk drug Analgin, the prices of formulations based on Analgin have been fixed, *suo moto*. As per present practice, while fixing the prices of formulations, 8% incidental charges which covers sales tax, octroi etc. are allowed if the formulation happens to be a leader pack or the bulk drug involved therein is not manufactured by the formulator itself. The ceiling prices of formulations based on bulk drug Analgin has accordingly been fixed, details of which are given in the annexed Statement. (*See* below)

(f) Since the prices have been fixed in accordance with the procedure being followed presently, question does not arise.

Statement

Ceiling prices of Analgin based Formulations

S. No.	Name of the formulation	Pack size	Pre-revised price	Revised prices
			Rs.	Rs.
1	Analgin tablets 500 mg.	10×10's strip	40.98	39.86
2	Do.	1000's tin/bottle	364.73	345.32
3	Analgin Injection, 500 mg/ml.	10×2 ml. Ampoule	22.52	22.24
4	Do.	5×5 ml. Ampoule	18.30	17.90
5	Do.	10 ml. vial	6.74	6.64
6	Do	30 ml. vial	14.44	14.10

Review of the amounts assessed by Special Team

1348. SHRI ASHOK NATH VERMA:

CHOWDHARY RAM SEWAK:

Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 72 given in the Rajya Sabha on the 30th April, 1990 and state

(a) whether the recoverable amounts have been reassessed after review against all the companies involved in the Supreme Court cases;

(b) if so, what are the details of those cases;

(c) what were the earlier amounts and what are the revised amounts in each case;

(d) what are the payments received so far including additional Payments, if any upto the 10th August, 1990;

(e) whether it is a fact that during review his Ministry found that full details were not collected by the Special Team;

(f) if so, how the review has been completed; and

(g) what action has been taken against the members of the Special Team for non-collection of vital details and non-verification thereof?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) Yes, Sir.

(b) to (d) A statement giving the requisite details is enclosed (*See* below).

(e) to (g) The review was undertaken based on the data already available with the Government. While communicating the revised tentative amounts to the companies involved in the Supreme Court case, they were requested to make available the details relating to stock, production, sales etc. so that the liabilities can be finalised. This issue is already receiving the attention.